Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop.

{"article_title":"Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop.","author":"NA","journal_title":"Cardiovascular diabetology","issn":"1475-2840 ; Electronic","isbn":"","publication_date":"20250207","volume":"24","issue":"1","first_page":"68","page_count":"","accession_number":"39920737","doi":"10.1186\/s12933-024-02550-2","publisher":"BioMed Central","doctype":"Journal Article","subjects":"Cardiology ","interest_area":["Endocrinology"," Cardiology"," Urology & Nephrology"],"abstract":"Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: Katharine Barnard-Kelly is founder and shareholder at Spotlight-AQ Ltd. KBK has received research support from Dexcom, Embecta, JDRF, Novo Nordisk and Roche Diabetes Care, and honoraria from Sanofi. Tadej Battelino has served on the advisory boards of Abbott, Boehringer Ingelheim, Dreamed Diabetes, Eli Lilly and Company, Indigo Diabetes, Medtronic, Novo Nordisk, and Sanofi. TB has received speaker\u2019s bureau honoraria from Abbott, Eli Lilly and Company, Medtronic, Novo Nordisk, Roche, and Sanofi. The University Medical Center has received research grant support from Abbott, GluSense, Medtronic, Novo Nordisk, Sandoz, Sanofi, and Zealand Pharma. Frank C. Brosius is a consultant for MAKSCIENTIFIC. Antonio Ceriello reports consulting and speaking for Bayer, Berlin-Chemie, Eli Lilly and Company, Guidotti, Merck, Novo Nordisk, Roche Diagnostics and Sanofi. Francesco Cosentino has nothing reported. Julian Elliott has nothing reported. James R. Gavin III has served on the advisory boards of Abbott Diabetes Care and Embecta, and on the speaker\u2019s bureaus of Boehringer Ingelheim and Eli Lilly and Company. Francesco Giorgino has served on the advisory boards of AstraZeneca, Eli Lilly and Company, Novo Nordisk, Roche Diabetes Care, Sanofi and as a consultant to AstraZeneca, Boehringer Ingelheim, LifeScan, Medimmune, Medtronic, Merck Sharp & Dohme, Roche Diabetes Care and Sanofi. FG has also received research support from Eli Lilly and Company and Roche Diabetes Care. Jennifer Green has nothing reported. Linong Ji declares that he has no competing interests. Monika Kellerer has served on advisory boards of Abbott Diabetes Care, Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Eli Lilly, NovoNordisk and Sanofi. Sue Koob has nothing reported. Mikhail Kosiborod reports consulting or advisory board participation for 35Pharma, Alnylam Pharmaceuticals, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly and Company, Esperion Therapeutics, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Pfizer, scPharmaceuticals, Sanofi, Structure Therapeutics, Vifor Pharma and Youngene Therapeutics. MK has also received honoraria from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and research grants from AstraZeneca, Boehringer Ingelheim and Pfizer. Nebojsa Lalic declares that he has no competing interests. Nikolaus Marx has received research grants from Boehringer Ingelheim and MSD, speaking fees form Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly and Company, MSD, Novo Nordisk, and Sanofi-Aventis and has served or serves on the advisory board of Amgen, Bayer, BMS, Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi-Aventis. Prashant Nedungadi has nothing reported. Christopher G. Parkin has nothing reported. Helena W. Rodbard declares that she has no competing interests. Ren\u00e9 D. R\u00f6tzer is employee of Sciarc GmbH. Lars Ryd\u00e9n declares that he has no competing interests related to this work. Wayne Sheu has nothing reported. Eberhard Standl declares that he has no competing interests. Britta Tendal Jeppesen declares that she has no competing interests. Pinar Topsever has received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and LifeScan, and has served on the speaker\u2019s bureau for AstraZeneca. PT received grant\/research support from PCDE, made possible by corporate sponsorship from AstraZeneca, Eli Lilly, Novo Nordisk, and Roche Diagnostics; the sponsors had no input into the study protocols. Per Olav Vandvik has nothing reported. Christoph Wanner received honoraria for steering committee and adboard participation as well as lecturing from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, MSD, Novo Nordisk and Sanofi. Oliver Schnell is founder and CEO at Sciarc GmbH, Baierbrunn, Germany.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=39920737&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Barnard-Kelly K, Battelino T, Brosius FC, Ceriello A, Cosentino F, Gavin JR 3rd, Giorgino F, Green J, Ji L, Kellerer M, Koob S, Kosiborod M, Lalic N, Marx N, Nedungadi P, Parkin CG, Rodbard HW, R\u00f6tzer RD, Ryd\u00e9n L, Sheu WH, Standl E, Jeppesen BT, Topsever P, Vandvik PO, Wanner C, Schnell O","Journal_Info":"Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE","Publication_Type":"Journal Article","Published_Date":"2025-02-07","Source":"Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Feb 07; Vol. 24 (1), pp. 68. Date of Electronic Publication: 2025 Feb 07.","Languages":"English","Electronic_ISSN":"1475-2840","MeSH_Terms":"Cardiovascular Diseases*\/therapy , Cardiovascular Diseases*\/diagnosis , Cardiovascular Diseases*\/epidemiology , Diabetes Mellitus*\/therapy , Diabetes Mellitus*\/diagnosis , Diabetes Mellitus*\/epidemiology , Obesity*\/therapy , Obesity*\/diagnosis , Obesity*\/epidemiology , Patient Reported Outcome Measures* , Renal Insufficiency, Chronic*\/therapy , Renal Insufficiency, Chronic*\/diagnosis , Renal Insufficiency, Chronic*\/epidemiology, Humans ; Practice Guidelines as Topic\/standards ; Quality of Life ; Treatment Outcome","Subjects":"Humans, Practice Guidelines as Topic standards, Quality of Life, Treatment Outcome, Cardiovascular Diseases therapy, Cardiovascular Diseases diagnosis, Cardiovascular Diseases epidemiology, Diabetes Mellitus therapy, Diabetes Mellitus diagnosis, Diabetes Mellitus epidemiology, Obesity therapy, Obesity diagnosis, Obesity epidemiology, Patient Reported Outcome Measures, Renal Insufficiency, Chronic therapy, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic epidemiology","Title_Abbreviations":"Cardiovascular diabetology","Volume":"24"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"39920737","RelevancyScore":"949","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"949.000122070313"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=39920737&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=39920737&authtype=shib&custid=ns346513&group=main&profile=eds"}